US3401221A - Treatment of urinary tract infection - Google Patents

Treatment of urinary tract infection Download PDF

Info

Publication number: US3401221A
Authority: US; United States
Prior art keywords: nitrofurantoin; urinary tract; mesh; treatment; tract infection
Prior art date: 1964-08-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

US392023A

Other languages

English (en)

Inventor

Borgmann August Russell

Kenyon J Hayes

Henry E Paul

Mary F Paul

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eaton Laboratories Inc

Warner Chilcott Pharmaceuticals Inc

Original Assignee

Norwich Pharmacal Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1964-08-25

Filing date

1964-08-25

Publication date

1968-09-10

1964-08-25 Application filed by Norwich Pharmacal Co filed Critical Norwich Pharmacal Co

1964-08-25 Priority to US392023A priority Critical patent/US3401221A/en

1965-05-19 Priority to NL6506369A priority patent/NL6506369A/xx

1965-05-25 Priority to DE19651492055 priority patent/DE1492055B1/de

1965-06-01 Priority to ES0313664A priority patent/ES313664A1/es

1965-06-03 Priority to IL23668A priority patent/IL23668A/en

1965-06-16 Priority to SE07949/65A priority patent/SE326186B/xx

1965-06-22 Priority to DK316165AA priority patent/DK116132B/da

1965-07-19 Priority to NO159004A priority patent/NO118491B/no

1965-07-21 Priority to JP40043717A priority patent/JPS4924651B1/ja

1965-08-05 Priority to FR27293A priority patent/FR4844M/fr

1965-08-09 Priority to GB34070/65A priority patent/GB1040980A/en

1965-08-18 Priority to FI1983/65A priority patent/FI42961B/fi

1965-08-24 Priority to AT774865A priority patent/AT261117B/de

1965-08-25 Priority to BE668774D priority patent/BE668774A/xx

1968-09-10 Application granted granted Critical

1968-09-10 Publication of US3401221A publication Critical patent/US3401221A/en

1982-07-29 Assigned to NORWICH EATON PUERTO RICO, INC. CARRETERA NO. 2, KM. 45.7, MANATI, PUERTO RICO 00701 A CORP. OF DE reassignment NORWICH EATON PUERTO RICO, INC. CARRETERA NO. 2, KM. 45.7, MANATI, PUERTO RICO 00701 A CORP. OF DE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: EATON LABORATORIES, INC. A CORP. OF DE

1982-11-15 Assigned to EATON LABORATORIES, INC. reassignment EATON LABORATORIES, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). EFFECTIVE 6-09-82 DELAWARE Assignors: NORWICH EATON PUERTO RICO

1985-09-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

208000019206 urinary tract infection Diseases 0.000 title description 4
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 17
229960000564 nitrofurantoin Drugs 0.000 description 16
239000013078 crystal Substances 0.000 description 13
206010047700 Vomiting Diseases 0.000 description 10
206010028813 Nausea Diseases 0.000 description 7
230000008693 nausea Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000002485 urinary effect Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
230000006735 deficit Effects 0.000 description 2
210000001635 urinary tract Anatomy 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002895 emetic Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000000034 method Methods 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000009974 thixotropic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Definitions

This invention relates to the therapy of urinary tract infection. More particularly it is concerned with improvements in the treatment of urinary tract infection with nitrofurantoin.
nitrofurantoin has come to 0ccupy a leading role in the treatment of infections of the urinary tract. Its widespread use in this respect has been attended with a minimum of side effects. Nonetheless, in common with other widely used therapeutic agents, its use has provoked side effects whose alleviation would be welcomed by the medical practitioner.
the most vexing side effect occasioned through the use of nitrofurantoin is that of nauesea and emesis which occurs in a relatively minor proportion of those to whom it is administered.
Various attempts to mitigate this problem through reduced dosage regimens, controlled diet or enteric coating of tablets containing it have not been wholly satisfactory thus depriving a relatively minor but nevertheless significant number of its benefits.
Nitrofurantoin crystals that vomited 50-60 mesh (300-250,:1.) 0 80-120 mesh (180-120 r) 6.3 140-200 mesh (10075,u) 15.6 200-400 mesh (-40,:t) 37.5
nitrofurantoin contemplated in this invention may be readily secured by saturating an appropriate solvent such as nitromethane therewith, advan tageously at elevated temperature, and allowing crystallization to take place spontaneously preferably on cooling slowly, or, if it is desired to hasten the process, a seed crystal may be introduced, until a sufiicient crop is secured. The deposited crop is filtered, dried, ground if necessary, and screened to obtain the desired crystal size range.
nitrofurantoin crystal size of this invention is preferably composed into capsules using suitable dispersants and excipients such as milk sugar and dextrose to insure even distribution and dispersion.
suitable dispersants and excipients such as milk sugar and dextrose to insure even distribution and dispersion.
Other acceptable pharmaceutical dosage forms such as a thixotropic suspension which will preserve the integrity of the crystal size may be employed.

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

US392023A 1964-08-25 1964-08-25 Treatment of urinary tract infection Expired - Lifetime US3401221A (en)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
US392023A US3401221A (en)	1964-08-25	1964-08-25	Treatment of urinary tract infection
NL6506369A NL6506369A (de)	1964-08-25	1965-05-19
DE19651492055 DE1492055B1 (de)	1964-08-25	1965-05-25	Neue Zubereitungsform des N-(5-Nitrofurfuryliden)-1-aminohydantoins
ES0313664A ES313664A1 (es)	1964-08-25	1965-06-01	Procedimiento para la preparacion de nitrofurantoina cristalina.
IL23668A IL23668A (en)	1964-08-25	1965-06-03	Crystalline nitrofuranthoin and processes for its preparation
SE07949/65A SE326186B (de)	1964-08-25	1965-06-16
DK316165AA DK116132B (da)	1964-08-25	1965-06-22	Fremgangsmåde til fremstilling af i det væsentlige kubiske nitrofurantoinkrystaller til oral indgift.
NO159004A NO118491B (de)	1964-08-25	1965-07-19
JP40043717A JPS4924651B1 (de)	1964-08-25	1965-07-21
FR27293A FR4844M (de)	1964-08-25	1965-08-05
GB34070/65A GB1040980A (en)	1964-08-25	1965-08-09	Improvements in or relating to the preparation of nitrofurantoin
FI1983/65A FI42961B (de)	1964-08-25	1965-08-18
AT774865A AT261117B (de)	1964-08-25	1965-08-24	Verfahren zur Herstellung einer hochwirksamen, gut verträglichen Zubereitungsform des N (5 Nitrofurfuryliden) 1 amino hydantoins
BE668774D BE668774A (de)	1964-08-25	1965-08-25

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US392023A US3401221A (en)	1964-08-25	1964-08-25	Treatment of urinary tract infection

Publications (1)

Publication Number	Publication Date
US3401221A true US3401221A (en)	1968-09-10

Family

ID=23548942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
US392023A Expired - Lifetime US3401221A (en)	1964-08-25	1964-08-25	Treatment of urinary tract infection

Country Status (14)

Country	Link
US (1)	US3401221A (de)
JP (1)	JPS4924651B1 (de)
AT (1)	AT261117B (de)
BE (1)	BE668774A (de)
DE (1)	DE1492055B1 (de)
DK (1)	DK116132B (de)
ES (1)	ES313664A1 (de)
FI (1)	FI42961B (de)
FR (1)	FR4844M (de)
GB (1)	GB1040980A (de)
IL (1)	IL23668A (de)
NL (1)	NL6506369A (de)
NO (1)	NO118491B (de)
SE (1)	SE326186B (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4772473A (en) *	1986-06-16	1988-09-20	Norwich Eaton Pharmaceuticals, Inc.	Nitrofurantoin dosage form
US4798725A (en) *	1986-06-16	1989-01-17	Norwich Eaton Pharmaceuticals, Inc.	Sustained release capsule
EP0410517A1 (de) *	1989-07-25	1991-01-30	Norwich Eaton Pharmaceuticals, Inc.	Flüssige Nitrofurantoinsuspension
US5332832A (en) *	1989-07-26	1994-07-26	Procter & Gamble Pharmaceuticals, Inc.	Nitrofurantoin crystals
US20060002997A1 (en) *	2002-08-23	2006-01-05	Puneet Shamar	Nitrofurantoin controlled release dosage form

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2348334C2 (de) *	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
DE3033919A1 (de) *	1980-09-09	1982-04-22	Bayer Ag, 5090 Leverkusen	Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung

1964
- 1964-08-25 US US392023A patent/US3401221A/en not_active Expired - Lifetime
1965
- 1965-05-19 NL NL6506369A patent/NL6506369A/xx unknown
- 1965-05-25 DE DE19651492055 patent/DE1492055B1/de active Pending
- 1965-06-01 ES ES0313664A patent/ES313664A1/es not_active Expired
- 1965-06-03 IL IL23668A patent/IL23668A/en unknown
- 1965-06-16 SE SE07949/65A patent/SE326186B/xx unknown
- 1965-06-22 DK DK316165AA patent/DK116132B/da unknown
- 1965-07-19 NO NO159004A patent/NO118491B/no unknown
- 1965-07-21 JP JP40043717A patent/JPS4924651B1/ja active Pending
- 1965-08-05 FR FR27293A patent/FR4844M/fr not_active Expired
- 1965-08-09 GB GB34070/65A patent/GB1040980A/en not_active Expired
- 1965-08-18 FI FI1983/65A patent/FI42961B/fi active
- 1965-08-24 AT AT774865A patent/AT261117B/de active
- 1965-08-25 BE BE668774D patent/BE668774A/xx unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4772473A (en) *	1986-06-16	1988-09-20	Norwich Eaton Pharmaceuticals, Inc.	Nitrofurantoin dosage form
US4798725A (en) *	1986-06-16	1989-01-17	Norwich Eaton Pharmaceuticals, Inc.	Sustained release capsule
EP0410517A1 (de) *	1989-07-25	1991-01-30	Norwich Eaton Pharmaceuticals, Inc.	Flüssige Nitrofurantoinsuspension
US5178880A (en) *	1989-07-25	1993-01-12	Norwich Eaton Pharmaceuticals, Inc.	Liquid suspensions of nitrofurantoin
US5332832A (en) *	1989-07-26	1994-07-26	Procter & Gamble Pharmaceuticals, Inc.	Nitrofurantoin crystals
US20060002997A1 (en) *	2002-08-23	2006-01-05	Puneet Shamar	Nitrofurantoin controlled release dosage form

Also Published As

Publication number	Publication date
IL23668A (en)	1969-07-30
JPS4924651B1 (de)	1974-06-25
AT261117B (de)	1968-04-10
ES313664A1 (es)	1965-09-01
FI42961B (de)	1970-09-02
NL6506369A (de)	1966-02-28
DE1492055B1 (de)	1971-05-13
FR4844M (de)	1967-02-20
BE668774A (de)	1965-12-16
DK116132B (da)	1969-12-15
NO118491B (de)	1970-01-05
SE326186B (de)	1970-07-20
GB1040980A (en)	1966-09-01

Legal Events

Date

Code

Title

Description

1982-07-29

AS

Assignment

Owner name: NORWICH EATON PUERTO RICO, INC. CARRETERA NO. 2,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:EATON LABORATORIES, INC. A CORP. OF DE;REEL/FRAME:004022/0627

Effective date: 19820609

1982-11-15

AS